{{Short description|Chemical compound}} {{Infobox drug | drug_name = | INN = | type = <!-- empty --> | image = HU6 structure.svg | image_class = skin-invert-image | alt = | caption = <!-- Clinical data --> | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = | ATCvet = | ATC_prefix = <!-- 'none' if uncategorised --> | ATC_suffix = <!-- Legal status --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU_comment = | legal_BR = <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C5, D1, D2, E, F1, F2, F3, F4 --> | legal_BR_comment = | legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA_comment = | legal_DE = <!-- Anlage I, II, III or Unscheduled --> | legal_DE_comment = | legal_NZ = <!-- Class A, B, C --> | legal_NZ_comment = | legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> | legal_UK_comment = | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US_comment = | legal_EU = | legal_EU_comment = | legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> | legal_UN_comment = | legal_status = Investigational <!-- Pharmacokinetic data --> | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = <!-- Identifiers --> | CAS_number = 2231311-68-3 | PubChem = 135205989 | ChemSpiderID = 128784125 | DrugBank = | UNII = 2U87AJU2ZZ | synonyms = HU6 <!-- Chemical and physical data --> | IUPAC_name = 5-[(2,4-Dinitrophenoxy)methyl]-1-methyl-2-nitroimidazole | C = 11 | H = 9 | N = 5 | O = 7 | StdInChI=1S/C11H9N5O7/c1-13-8(5-12-11(13)16(21)22)6-23-10-3-2-7(14(17)18)4-9(10)15(19)20/h2-5H,6H2,1H3 | StdInChIKey = LRJQZGXEGNOHBH-UHFFFAOYSA-N | smiles = CN1C(=CN=C1[N+](=O)[O-])COC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-] }}
'''Dinifedriton''', also known as '''HU6''', is a prodrug of the mitochondrial uncoupler 2,4-dinitrophenol (DNP) that is intended to "minimize the rapid absorption and high peak blood concentrations of DNP to provide a wider therapeutic index and improve safety."<ref>{{cite journal |last1=Noureddin |first1=Mazen |last2=Khan |first2=Shaharyar |last3=Portell |first3=Francisco |last4=Jorkasky |first4=Diane |last5=Dennis |first5=Jameel |last6=Khan |first6=Omer |last7=Johansson |first7=Lars |last8=Johansson |first8=Edvin |last9=Sanyal |first9=Arun J |title=Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial |journal=The Lancet Gastroenterology & Hepatology |date=December 2023 |volume=8 |issue=12 |pages=1094–1105 |doi=10.1016/S2468-1253(23)00198-X|doi-access=free |pmid=37806314 }}</ref> Developed by Rivus Pharmaceuticals, the drug is tested to reduce weight and liver fat in humans with risk factors for metabolic dysfunction-associated steatohepatitis. In a phase 2a trial, the higher dosage levels reduced liver fat on average by more than 30 percent and also reduced body weight significantly.<ref>{{cite journal |last1=Harrison |first1=Stephen A. |last2=Loomba |first2=Rohit |last3=Dubourg |first3=Julie |last4=Ratziu |first4=Vlad |last5=Noureddin |first5=Mazen |title=Clinical Trial Landscape in NASH |journal=Clinical Gastroenterology and Hepatology |date=July 2023 |volume=21 |issue=8 |pages=2001–2014 |doi=10.1016/j.cgh.2023.03.041|pmid=37059159 |doi-access=free }}</ref><ref>{{cite journal |last1=Noureddin |first1=Mazen |last2=Khan |first2=Shaharyar |last3=Portell |first3=Francisco |last4=Jorkasky |first4=Diane |last5=Dennis |first5=Jameel |last6=Khan |first6=Omer |last7=Johansson |first7=Lars |last8=Johansson |first8=Edvin |last9=Sanyal |first9=Arun J |title=Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial |journal=The Lancet Gastroenterology & Hepatology |date=December 2023 |volume=8 |issue=12 |pages=1094–1105 |doi=10.1016/S2468-1253(23)00198-X|doi-access=free |pmid=37806314 }}</ref> A phase 2b trial was launched in late 2023.<ref>{{cite news |title=Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments |url=https://finance.yahoo.com/news/rivus-pharmaceuticals-announces-expansion-hu6-130000050.html |access-date=3 December 2023 |work=Yahoo Finance |date=15 November 2023}}</ref> A phase 2b trial in patients with metabolic dysfunction-associated steatohepatitis was subsequently initiated.<ref>{{cite news |title=Rivus Pharmaceuticals Announces Expansion of HU6 Clinical Program and New Leadership Appointments |url=https://finance.yahoo.com/news/rivus-pharmaceuticals-announces-expansion-hu6-130000050.html |access-date=3 December 2023 |work=Yahoo Finance |date=15 November 2023}}</ref> Data from this study are expected to be reported in 2025. Additionally, a phase 2a study was performed in patients suffering from heart failure with preserved ejection fraction, a disease that is mediated by visceral fat and obesity. The study achieved the primary endpoint of weight loss, as well as a number of secondary endpoints.<ref>{{Cite web |date=September 30, 2024 |title=Rivus Pharmaceuticals Announces New Clinical Data from Phase 2a HuMAIN Trial Demonstrating Significant Weight Loss with HU6 in Patients with Obesity-Related HeartFailure |url=https://www.rivuspharma.com/wp-content/uploads/2024/09/HFSA_Press-Release-final.pdf}}</ref>
==References== {{reflist}}
Category:Prodrugs Category:Uncouplers Category:Experimental drugs developed for non-alcoholic fatty liver disease Category:Experimental anti-obesity drugs Category:Nitrobenzene derivatives Category:Nitroimidazoles